Mikael Asp has been appointed the new CEO of Oasmia pharmaceutical company. He succeeds Julian Aleksov, who has been nominated as the company’s new chairman of the board of directors. Current Board President Joel Lemon announced that he wishes to resign.
Asp currently is head of quality assurance at the company and has many years of experience working within the international pharmaceutical industry, the company says. He previously worked in management at Oasmia and has been employed there since 2013.
Aleksov, one of the company’s founders, has been CEO and a board member since the company started, according to LifeScience Sweden.
Oasmia’s Board of Directors is proposing issuing new shares, resulting in an increase of the share capital to a maximum of $1.5 million, in addition to the share capital increase, which may result from previous appropriations, and are valid until the next annual general meeting.
The authorization to issue new shares is requested as the company ramps up marketing efforts in the United States, Russia and other markets in Asia. Oasmia also has announced that it is considering a secondary listing on the Nasdaq.
Source: LifeScience Sweden